PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Sprinzl, M.F. ; Reisinger, F. ; Puschnik, A. ; Ringelhan, M. ; Ackermann, K. ; Hartmann, D.* ; Schiemann, M. ; Weinmann, A.* ; Galle, P.R.* ; Schuchmann, M.* ; Friess, H.* ; Otto, G.* ; Heikenwälder, M. ; Protzer, U.

Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells.

Hepatology 57, 2358-2368 (2013)
Verlagsversion Volltext DOI PMC
Open Access Gold
BACKGROUND: Alternatively polarized macrophages (MΦ) shape the microenvironment of hepatocellular carcinoma (HCC) and temper anti-cancer immune responses. We investigated if Sorafenib alters the HCC microenvironment by restoring classical macrophage polarization and triggering tumor-directed NK cell responses. METHODS: In vivo experiments were conducted with Sorafenib (25 mg/kg) treated C57BL/6 wild-type as well as HBV and lymphotoxin transgenic mice with and without HCC. Monocyte derived MΦ or tumor-associated macrophages (TAM) isolated from HCC tissue were treated with Sorafenib (0.07-5.0 µg/ml) and co-cultured with autologous NK cells. MΦ and NK cell activation was analyzed by flow cytometry and killing assays, respectively. Cytokine and growth factor release was measured by ELISA. RESULTS: Short-term administration of Sorafenib triggered activation of hepatic NK cells in wild-type and tumor bearing mice. In vitro, Sorafenib sensitized MΦ to LPS reverting alternative MΦ polarization and enhanced IL12 secretion (P=0.0133). NK cells activated by Sorafenib-treated MΦ showed increased degranulation (15.3±0.2% vs. 32.0±0.9%, P<0.0001) and IFNγ secretion (2.1±0.2% vs. 8.0±0.2%, P<0.0001) upon target cell contact. Sorafenib-triggered NK cell activation was verified by co-culture experiments using TAM. Sorafenib-treated MΦ increased cytolytic NK cell function against K562, Raji and HepG2 target cells in a dose-dependent manner. Neutralization of IL12 or IL18 as well as inhibition of the NFκB pathway reversed NK cell activation in MΦ/NK co-cultures. CONCLUSION: Sorafenib triggers pro-inflammatory activity of TAM and subsequently induces anti-tumoral NK cell responses in a cytokine and NFĸB-dependent fashion. This observation is relevant for HCC therapy, as Sorafenib is a compound in clinical use, which reverses alternative polarization of TAM in HCC.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
12.003
2.848
100
111
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter liver cancer; therapy; microenvironment; immunology; HCC; Colony-stimulating Factor ; Hepatocellular-carcinoma Patients ; Tumor-associated Macrophages ; Regulatory T-cells ; Ifn-gamma ; Human Monocytes ; Nk Cells ; Induced Apoptosis ; Interferon-gamma ; Factor-i
Sprache englisch
Veröffentlichungsjahr 2013
HGF-Berichtsjahr 2013
ISSN (print) / ISBN 0270-9139
e-ISSN 1527-3350
Zeitschrift Hepatology
Quellenangaben Band: 57, Heft: 6, Seiten: 2358-2368 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort Hoboken, NJ
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
Institute of Molecular Immunology (IMI)
POF Topic(s) 30203 - Molecular Targets and Therapies
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-502700-003
G-551600-001
G-501790-003
G-520100-001
G-502700-004
PubMed ID 23424039
DOI 10.1002/hep.26328
WOS ID WOS:000320276400029
Scopus ID 84879111551
Erfassungsdatum 2013-04-12
[➜Korrektur melden]